Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 12/20 | 0.58 |
| ▸ | CTSK | P43235 | 11/20 | 0.58 |
| ▸ | CTSB | P07858 | 4/20 | 0.57 |
| ▸ | CTSL | P07711 | 2/20 | 0.57 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.54 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | CTSG | P08311 | 1/20 | 0.48 |
| ▸ | CMA1 | P23946 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16935712 | 1.00 | CTSS (0.58) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL2617261 | 1.00 | CTSS (0.58) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL539373 | 0.96 | CTSS (0.62) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL539374 | 0.96 | CTSS (0.62) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL31524193 | 0.94 | CTSS (0.59) | CTSSCTSKCTSBCTSLNLRP3 | |
| SCHEMBL3498722 | 0.92 | PTPN1 (0.62) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL3498720 | 0.92 | PTPN1 (0.62) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL23419674 | 0.90 | CTSS (0.56) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL5151368 | 0.90 | CTSS (0.56) | CTSSCTSKCTSBCTSLPTPN1 | |
| SCHEMBL21663693 | 0.89 | CTSS (0.57) | CTSSCTSKCTSBCTSLPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654818-B2 | Furane derivatives as inhibitors of ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-19 | — | — | US | disclosed |
| US-10654818-B2 | Furane derivatives as inhibitors of ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-19 | — | — | US | disclosed |
| EP-3383865-B1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | Bayer Pharma AG (DE) | 2020-01-29 | — | — | EP | disclosed |
| EP-3383865-B1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | Bayer Pharma AG (DE) | 2020-01-29 | — | — | EP | disclosed |
| US-20190218196-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-07-18 | — | — | US | disclosed |
| US-20190218196-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-07-18 | — | — | US | disclosed |
| EP-3383865-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | Bayer Pharma Aktiengesellschaft (DE) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017093272-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-08 | — | — | WO | disclosed |
| WO-2017093272-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218196-A1 | FURANE DERIVATIVES AS INHIBITORS OF ATAD2 | ATAD2, ATAD2B, TAF1L | CTSS 3972/4885CTSK 3752/4885CTSB 3425/4885 |
| US-10654818-B2 | Furane derivatives as inhibitors of ATAD2 | ATAD2, ATAD2B, TAF1L | CTSS 3972/4885CTSK 3752/4885CTSB 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.